Suckert T, Rassamegevanon T, Müller J, Dietrich A, Graja A, Reiche M, Löck S, Krause M, Beyreuther E, von Neubeck C.
Applying Tissue Slice Culture in Cancer Research-Insights from Preclinical Proton Radiotherapy.
Cancers (Basel). 2020;12(6):1589.

Arndt C, Loureiro LR, Feldmann A, Jureczek J, Bergmann R, Máthé D, Hegedüs N, Berndt N, Koristka S, Mitwasi N, Fasslrinner F, Lamprecht C, Kegler A, Hoffmann A, Bartsch T, Köseer AS, Egan G, Schmitz M, Hořejší V, Krause M, Dubrovska A, Bachmann M.
UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells.
Oncoimmunology. 2020;9(1):1743036.

Meneceur S, Linge A, Meinhardt M, Hering S, Löck S, Bütof R, Krex D, Schackert G, Temme A, Baumann M, Krause M, von Neubeck C.
Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.
Cancers (Basel). 2020;12(4):871.

Schmidt S, Linge A, Grosser M, Lohaus F, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S;
German Cancer Consortium Radiation Oncology Group.
Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
J Mol Diagn. 2020;22(6):801-810.

Suckert T, Müller J, Beyreuther E, Azadegan B, Brüggemann A, Bütof R, Dietrich A, Gotz M, Haase R, Schürer M, Tillner F, von Neubeck C, Krause M, Lühr A.
High-precision image-guided proton irradiation of mouse brain sub-volumes.
Radiother Oncol. 2020;146:205-212.

Krause M, Alsner J, Linge A, Bütof R, Löck S, Bristow R.
Specific requirements for translation of biological research into clinical radiation oncology.
Mol Oncol. 2020;14(7):1569-1576.

Dutz A, Agolli L, Bütof R, Valentini C, Baumann M, Lühr A, Löck S, Krause M.
Neurocognitive function and quality of life after proton beam therapy for brain tumour patients.
Radiother Oncol. 2020;143:108-116.

Wohlfahrt P, Möhler C, Enghardt W, Krause M, Kunath D, Menkel S, Troost EGC, Greilich S, Richter C.
Refinement of the Hounsfield look-up table by retrospective application of patient-specific direct proton stopping-power prediction from dual-energy CT.
Med Phys. 2020;47(4):1796-1806.

Zschaeck S, Li Y, Bütof R, Lili C, Hua W, Troost ECG, Beck M, Amthauer H, Kaul D, Kotzerke J, Baur ADJ, Ghadjar P, Baumann M, Krause M, Hofheinz F.
Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer.
Int J Cancer. 2020;147(5):1427-1436.

Bütof R, Löck S, Soliman M, Haase R, Perrin R, Richter C, Appold S, Krause M, Baumann M.
Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy.
Radiother Oncol. 2020;143:44-50.

Gurtner K, Kryzmien Z, Koi L, Wang M, Benes CH, Hering S, Willers H, Baumann M, Krause M.
Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.
Int J Cancer. 2020;147(2):472-477.


Rassamegevanon T, Löck S, Baumann M, Krause M, von Neubeck C.
Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual γH2AX.
Radiother Oncol. 2019;139:94-100.

Eulitz J, Lutz B, Wohlfahrt P, Dutz A, Enghardt W, Karpowitz C, Krause M, Troost EGC, Lühr A.
A Monte Carlo based radiation response modelling framework to assess variability of clinical RBE in proton therapy.
Phys Med Biol. 2019;64(22):225020.

Eulitz J, Troost EGC, Raschke F, Schulz E, Lutz B, Dutz A, Löck S, Wohlfahrt P, Enghardt W, Karpowitz C, Krause M, Lühr A.
Predicting late magnetic resonance image changes in glioma patients after proton therapy.
Acta Oncol. 2019;58(10):1536-1539.

Raschke F, Wesemann T, Wahl H, Appold S, Krause M, Linn J, Troost EGC.
Reduced diffusion in normal appearing white matter of glioma patients following radio(chemo)therapy.
Radiother Oncol. 2019;140:110-115.

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Budach V, Tinhofer I; DKTK-ROG.
Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eur J Cancer. 2019;116:67-76.

Meneceur S, Löck S, Gudziol V, Hering S, Bütof R, Rehm M, Baumann M, Krause M, von Neubeck C.
Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
Radiother Oncol. 2019;137:24-31.

Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE, Baretton GB, Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M, Troost EGC.
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Radiother Oncol. 2019;135:43-50.

Oesten H, Neubeck CV, Jakob A, Enghardt W, Krause M, McMahon SJ, Grassberger C, Paganetti H, Lühr A.
Predicting In Vitro Cancer Cell Survival Based on Measurable Cell Characteristics.
Radiat Res. 2019;191(6):532-544.

Linge A, Schmidt S, Lohaus F, Krenn C, Bandurska-Luque A, Platzek I, von Neubeck C, Appold S, Nowak A, Gudziol V, Buchholz F, Baretton GB, Baumann M, Löck S, Krause M.
Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy.
Clin Transl Radiat Oncol. 2019;16:40-47.

Wagner F, Hölig U, Wilczkowski F, Plesca I, Sommer U, Wehner R, Kießler M, Jarosch A, Flecke K, Arsova M, Tunger A, Bogner A, Reißfelder C, Weitz J, Schäkel K, Troost EGC, Krause M, Folprecht G, Bornhäuser M, Bachmann MP, Aust D, Baretton G, Schmitz M.
Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc Monocytes in Rectal Cancer.
Front Immunol. 2019;10:602.

Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S.
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Acta Oncol. 2019;58(6):916-925.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Perrin R, Appold S, Krause M, Steinbach J, Kotzerke J, Hofheinz F, Zips D, Baumann M, Troost EGC.
Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients.
Clin Transl Radiat Oncol. 2019;15:108-112.

Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova II, Negro G, Aschenbrenner B, Eisenhofer G, Richter S, Heiden S, Porrmann J, Klink B, Schwager C, Dowle AA, Hein L, Kunz-Schughart LA, Abdollahi A, Lohaus F, Krause M, Baumann M, Linge A, Dubrovska A.
The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity.
Clin Cancer Res. 2019;25(10):3152-3163.

Lohaus F, Zöphel K, Löck S, Wirth M, Kotzerke J, Krause M, Baumann M, Troost EGC, Hölscher T.
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Eur Urol. 2019;75(4):548-551.

Joos S, Nettelbeck DM, Reil-Held A, Engelmann K, Moosmann A, Eggert A, Hiddemann W, Krause M, Peters C, Schuler M, Schulze-Osthoff K, Serve H, Wick W, Puchta J, Baumann M.
German Cancer Consortium (DKTK) - A national consortium for translational cancer research.
Mol Oncol. 2019;13(3):535-542.

Kurz C, Süss P, Arnsmeyer C, Haehnle J, Teichert K, Landry G, Hofmaier J, Exner F, Hille L, Kamp F, Thieke C, Ganswindt U, Valentini C, Hölscher T, Troost E, Krause M, Belka C, Küfer KH, Parodi K, Richter C.
Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization.
Z Med Phys. 2019;29(3):216-228.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Abolmaali N, Seidlitz A, Appold S, Krause M, Steinbach J, Kotzerke J, Zips D, Baumann M, Troost EGC.
FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Radiother Oncol. 2019;130:97-103.

Aktar R, Dietrich A, Tillner F, Kotb S, Löck S, Willers H, Baumann M, Krause M, Bütof R.
Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios.
Br J Radiol. 2019;92(1095):20180539.

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger H, Ganswindt U, Henke M, Belka C.
A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.
Clin Cancer Res. 2019;25(5):1505-1516

Leger S, Zwanenburg A, Pilz K, Zschaeck S, Zöphel K, Kotzerke J, Schreiber A, Zips D, Krause M, Baumann M, Troost EGC, Richter C, Löck S.
CT imaging during treatment improves radiomic models for patients with locally advanced head and
neck cancer.
Radiother Oncol. 2019;130:10-17.

Dutz A, Lühr A, Agolli L, Troost EGC, Krause M, Baumann M, Vermeren X, Geismar D, Schapira EF, Bussière M, Daly JE, Bussière MR, Timmermann B, Shih HA, Löck S.
Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours.
Radiother Oncol. 2019;130:164-171.

Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Aust DE, Klink B, Weitz J, Stange DE.
Human gastric cancer modelling using organoids.
Gut. 2019;68(2):207-217.


Robert G. Bristow, Brian Alexander, Michael Baumann, Scott V. Bratman, J. Martin Brown, Kevin Camphausen, Peter Choyke, ..., Mechthild Krause, u. a. „Combining Precision Radiotherapy with Molecular Targeting and Immunomodulatory Agents: A Guideline by the American Society for Radiation Oncology“. The Lancet. Oncology 19, 5 (2018): e240–51.

M. Buthut, R. Haussmann, A. Seidlitz, M. Krause, und M. Donix. „Cognitive deficits following brain tumor radiation therapy“. Der Nervenarzt 89, 4 (2018): 423–30.

Stephanie E. Combs, Maximilian Niyazi, Sebastian Adeberg, Nina Bougatf, David Kaul, Daniel F. Fleischmann, Arne Gruen, ..., Mechthild Krause, u. a. „Re-Irradiation of Recurrent Gliomas: Pooled Analysis and Validation of an Established Prognostic Score-Report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK)“. Cancer Medicine 7, 5 (2018): 1742–49.

Chiara De-Colle, Apostolos Menegakis, David Mönnich, Stefan Welz, Simon Boeke, Bence Sipos, Falko Fend, ..., Mechthild Krause, u. a. „SDF-1/CXCR4 Expression Is an Independent Negative Prognostic Biomarker in Patients with Head and Neck Cancer after Primary Radiochemotherapy“. Radiotherapy and Oncology, 26, 1 (2018): 125–31.

Marlene Hechtner, Mechthild Krause, Jochem König, Steffen Appold, Beate Hornemann, Susanne Singer, und Michael Baumann. „Long-Term Quality of Life in Inoperable Non-Small Cell Lung Cancer Patients Treated with Conventionally Fractionated Compared to Hyperfractionated Accelerated Radiotherapy - Results of the Randomized CHARTWEL Trial“. Radiotherapy and Oncology, 126, 2 (2018): 283–90.

Mohammad Hreib, und Mechthild Krause. „No evidence for reduced late toxicity with dose reduction in the elective lymph node region in primary radiochemotherapy of head and neck tumors“. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft, 194, 7 (2018): 697–98.

Armin Jarosch, Ulrich Sommer, Andreas Bogner, Christoph Reißfelder, Jürgen Weitz, Mechthild Krause, Gunnar Folprecht, Gustavo B. Baretton, und Daniela E. Aust. „Neoadjuvant Radiochemotherapy Decreases the Total Amount of Tumor Infiltrating Lymphocytes, but Increases the Number of CD8+/Granzyme B+ (GrzB) Cytotoxic T-Cells in Rectal Cancer“. Oncoimmunology 7, 2 (2018): e1393133.

Annett Linge, Ulrike Schötz, Steffen Löck, Fabian Lohaus, Cläre von Neubeck, Volker Gudziol, Alexander Nowak, ..., Mechthild Krause, u. a. „Comparison of Detection Methods for HPV Status as a Prognostic Marker for Loco-Regional Control after Radiochemotherapy in Patients with HNSCC“. Radiotherapy and Oncology, 127, 1 (2018): 27–35.

Armin Lühr, Cläre von Neubeck, Mechthild Krause, und Esther G. C. Troost. „Relative Biological Effectiveness in Proton Beam Therapy - Current Knowledge and Future Challenges“. Clinical and Translational Radiation Oncology 9 (2018): 35–41.

Armin Lühr, Cläre von Neubeck, Jörg Pawelke, Annekatrin Seidlitz, Claudia Peitzsch, Søren M. Bentzen, Thomas Bortfeld, ..., Mechthild Krause, u. a. „‚Radiobiology of Proton Therapy‘: Results of an International Expert Workshop“. Radiotherapy and Oncology, 128, 1 (2018): 56–67.

Maximilian Niyazi, Sebastian Adeberg, David Kaul, Anne-Laure Boulesteix, Nina Bougatf, Daniel F. Fleischmann, Arne Grün, ..., Mechthild Krause, u. a. „Independent Validation of a New Reirradiation Risk Score (RRRS) for Glioma Patients Predicting Post-Recurrence Survival: A Multicenter DKTK/ROG Analysis“. Radiotherapy and Oncology, 127, 1 (2018): 121–27.

Jan Petr, Ivan Platzek, Frank Hofheinz, Henri J. M. M. Mutsaerts, Iris Asllani, Matthias J. P. van Osch, Annekatrin Seidlitz, ..., Mechthild Krause, u. a. „Photon vs. Proton Radiochemotherapy: Effects on Brain Tissue Volume and Perfusion“. Radiotherapy and Oncology, 128, 1 (2018): 121–27.

Treewut Rassamegevanon, Steffen Löck, Michael Baumann, Mechthild Krause, und Cläre von Neubeck. „Heterogeneity of ΓH2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors“. International Journal of Molecular Sciences 19, 9 (2018).

Stefan Schmidt, Annett Linge, Alex Zwanenburg, Stefan Leger, Fabian Lohaus, Constanze Krenn, Steffen Appold, ..., Mechthild Krause, u. a. „Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(Chemo)Therapy“. Clinical Cancer Research, 24, 6 (2018): 1364–74.

Stefan Stangl, Nikoletta Tontcheva, Wolfgang Sievert, Maxim Shevtsov, Minli Niu, Thomas E. Schmid, Steffi Pigorsch, ..., Mechthild Krause, u. a. „Heat Shock Protein 70 and Tumor-Infiltrating NK Cells as Prognostic Indicators for Patients with Squamous Cell Carcinoma of the Head and Neck after Radiochemotherapy: A Multicentre Retrospective Study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)“. International Journal of Cancer 142, 9 (2018): 1911–25.



Krause M, Dubrovska A, Linge M, Baumann M (2017) Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev 109, 63-73.

Liebscher S, Koi L, Löck S, Muders MH, Krause M (2017) The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC 3 prostate cancer in vitro and in vivo. Clin Transl Rad Onc 2, 7-12.

Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77, 2018-28.

Zschaeck S, Löck S, Leger S, Haase R, Bandurka-Luque A, Appold S, Kotzerke J, Zips D, Richter C, Gudziol V, Schreiber A, Zöphel K, Baumann M, Krause M (2017) FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. Radiother Oncol 122, 437-44.

Francolini G, Thomsen MS, Yates ES, Kirkove C, Jensen I, Blix ES, Kamby C, Nielsen MH, Krause M, Berg M, Mjaaland I Schreiber A, Kasti UM, Boye K, Offersen BV (2017) Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. Radiother Oncol 123(2):282-287.

Balermpas P, Rödel F, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Sak A, Stuschke M, Gkika E, Grosu AL, Abdollahi A, Debus J, Stangl S, Ganswindt U, Belka C, Pigorsch S, Multhoff G, Combs SE, Welz S, Zips D, Lim SY, Rödel C, Fokas E; DKTK-ROG (2017) The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 141(3):594-603.

Zschaeck S, Hofheinz F, Zöphel K, Bütof R, Jentsch C, Schmollack J, Löck S, Kotzerke J, Baretton G, Weitz J, Baumann M, Krause M (2017) Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging, (epub ahead print)

Lühr A, Löck S, Jakobi A, Stützer K, Bandurska-Luque A, Vogelius IR, Enghardt W, Baumann M, Krause M (2017) Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. Z Med Phys, pii: S0939-3889(17)30098-3 (epub ahead print)

Rassamegevanon T, Löck S, Range U, Krause M, Baumann M, von Neubeck C (2017) Tumor heterogeneity determined with a γH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models. Radiother Oncol. (epub ahead print)

Weber DC, Abrunhosa-Branquinho A, Bolsi A, Kacperek A, Dendale R, Geismar D, Bachtiary B, Hall A, Heufelder J, Herfarth K, Debus J, Amichetti M, Krause M, Orecchia R, Vondracek V, Thariat J, Kajdrowicz T, Nilsson K, Grau C (2017) Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiother Oncol. (epub ahead print)


Richter C, Pausch G, Barczyk S, Priegnitz M, Keitz I, Thiele J, Smeets J, van der Stappen F, BombelliL, Fiorini C, Hotoiu L, Perali I, Prieels D, Enghardt W, Baumann M (2016) First clinical application of a prompt gamma based in vivo proton range verification system. Radiother Oncol 118: 232-237.

Lattermann A, Baumann M, Krause M (2016) Clinical trials for personalized glioblastoma radiotherapy: Markers for efficacy and late toxicity but often delayed treatment – does that matter? Radiother Oncol 118, 211-13.

Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Jöhrens K, Weichert W, Linge A, Lohaus F, Krause M, Neumann K, Endris V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu A, Abdollahi A, Debus J, Belka C, Pigorsch S, combs S, Mönnich D, Zips D, Baumann M (2016) Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. Eur J Cancer 57, 78-86.

Tawk B, Schwager C, Deffaa O, Dyckhoff G, Warta R, Linge A, Krause M, Weichert W, Baumann M, Herold-Mende C, Debus J, Abdollahi A (2016) Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiother Oncol 118: 350-358.

Coleman CN, Higgins GS, Brown JM, Baumann M, Kirsch DG, Willers H, Prasanne PGS, Dewhirst MW, Bernhard EJ, Ahmed MM (2016) Improving the predictive value of preclinical studies in support of radiotherapy clinical trials. Clin Cancer Res. 22(13):3138-47.

Baumann M, Krause M, Overgaard J, Debus J, Bentzen S, Daartz J, Richter c, Zips D, Bortfeld T (2016) Radiation oncology in the era of precision medicine. Nat Rev Cancer 16, 234-46.

Linge A, Löck S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, Jütz M, Abdollahi A, Debus J, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Bayer C, Belka C, Pigorsch S, Combs S, Welz S, Zips D, Buchholz F, Aust DE,  Baretton G, Thames HD, Dubrovska A, Alsner J, Overgaard J, Baumann M, Krause M for the DKTK-ROG (2016) Low CSC marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG. Clin Cancer Res 22, 2639-49.

Skripcak T, Just U, Simon M, Büttner D, Lühr A, Baumann M, Krause M (2016) Towards Distributed Conduction of Large Scale Studies in Radiation Therapy and Oncology: open source system integration approach. IEEE J Biomed Health Inform 20, 2168-2194.

Linge A, Löck S, Krenn C, Lohaus F, Nowak A, Gudziol V, Baretton G, Buchholz F, Appold S, Baumann M, Krause M (2016) Independent validation of the prognostic value of CSC marker expression and hypoxia-induced gene expression for HNSCC after postoperative radiotherapy. Clin Transl Rad Onc 1, 19-26.

Linge A, Lohaus F, Löck S, Nowak A, Gudziol V, Valentini C, Haase R, von Neubeck C, Jütz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Abdollahi A, Debus J, Bayer C, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M  for the DKTK-ROG (2016) HPV status, tumour volume, cancer stem cell marker expression and hypoxia status identify good prognosis subgroups in HNSCC after primary radiochemotherapy: results from a multicentre exploratory study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 121, 364-373.

Jentsch C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Krause M, Zips D, Troost EG, Löck S, Kotzerke J, Steinbach J, Thames H, Baumann M, Beuthien-Baumann B (2016) Impact of pre- and early per-treatment FDG-PET based dose-escalation an local tumour control in fractionated irradiated FaDu xenograft tumours. Radiother Oncol 121, 447-52.

Zschaeck S, Simon M, Löck S, Troost EG, Stützer K, Wohlfahrt P, Appold S, Makocki S, Bütof R, Richter C, Baumann M, Krause M (2016) PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced Non-Small-Cell Lung Carcinomas (NSCLC): study protocol for a randomized controlled trial. Trials 17, 543.


Brada M, Pope A, Baumann (2015) SABR in NSCLC - The beginning of the end or the end of the beginning? Radiother Oncol 114: 135–137

Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke K-D, Ghadjar P (2015) Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C Is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95-06 Randomized Phase III Trial. Int J Radiat Oncol Biol Phys 91: 916–924

De Ryck T, Van Impe A, Vanhoecke BW, Heyerick A, Vakaet L, De Neve W, Müller D, Schmidt M, Dörr W, Bracke ME (2015) 8-prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis: Cell culture and murine model. Strahlenther Onkol 191: 429–436

Dietrich A, Koi L, Zöphel K, Sihver W, Kotzerke J, Baumann M, Krause M (2015) Improving external beam radiotherapy by combination with internal irradiation. Br J Radiol 20150042

Eke I, Zscheppang K, Dickreuter E, Hickmann L, Mazzeo E, Unger K, Krause M, Cordes N (2015). Simultaneous β1 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer. J Natl Cancer Inst 107

Gruber S, Schmidt M, Bozsaky E, Wolfram K, Haagen J, Habelt B, Puttrich M, Dörr W (2014) Modulation of radiation-induced oral mucositis by pentoxifylline: Preclinical studies. Strahlenther Onkol

Gruber S, Hamedinger D, Bozsaky E, Schmidt M, Wolfram K, Haagen J, Habelt B, Puttrich M, Dörr W (2015) Local hypoxia in oral mucosa (mouse) during daily fractionated irradiation - Effect of pentoxifylline. Radiother Oncol

Jaffray DA, Atun R, Barton M, Baumann M, Gospodarowicz M, Hoskin P, Knaul FM, Lievens Y, Rosenblatt E, Torode J, van Dyk J, Vikram B, on behalf of the Union for International Cancer Control´s Global Task Force on Radiotherapy for Cancer Control (2015) Radiation therapy and the global health agenda. Clin Oncol (R Coll Radiol) 27: 67–69

Jakobi A, Bandurska-Luque A, Stützer K, Haase R, Löck S, Wack L-J, Mönnich D, Thorwarth D, Perez D, Lühr A, Zips D, Krause M, Baumann M, Perrin R, Richter C (2015) Identification of patient benefit from proton therapy for advanced head and neck cancer patients based on individual and subgroup NTCP analysis. Int J Radiat Oncol Biol Phys

Jentsch C, Beuthien-Baumann B, Troost EGC, Shakirin G (2015) Validation of functional imaging as a biomarker for radiation treatment response. Br J Radiol 20150014

Krause M, Supiot S (2015) Advances in Radiotherapy special feature. Br J Radiol 20150412

Krause M, Petersen C, Offersen B, Baumann M (2015) Regional radiotherapy in high-risk breast cancer: Is the issue solved? Br J Radiol 20150071

Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob TJ, Laban S, Kasten-Pisula U, Petersen C, Baumann M, Krause M, Dikomey E (2015) Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Radiother Oncol

Löck S, Roth K, Skripcak T, Worbs M, Helmbrecht S, Jakobi A, Just U, Krause M, Baumann M, Enghardt W, Lühr A (2015) Implementation of a software for REmote COMparison of PARticlE and photon treatment plans: ReCompare. Z Med Phys

Menegakis A, von Neubeck C, Yaromina A, Thames H, Hering S, Hennenlotter J, Scharpf M, Noell S, Krause M, Zips D, Baumann M (2015) γH2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. Radiother Oncol

Von Neubeck C, Geniza MJ, Kauer PM, Robinson RJ, Chrisler WB, Sowa MB (2015) The effect of low dose ionizing radiation on homeostasis and functional integrity in an organotypic human skin model. Mutat Res 775: 10–18

Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol J-P, Remouchamps V, Verhoeven K,Weltens C, Arenas M, Gbrys D, Kopek N, Krause M, Lundstedt D Marinko T, Montero A, Yarnold J, Portmans P (2015) ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 114: 3–10

Oppelt M, Baumann M, Bergmann R, Beyreuther E, Brüchner K, Hartmann J, Karsch L, Krause M, Laschinsky L, Leßmann E, Nicolai M, Reuter M, Richter C, Sävert A, Schnell M, Schürer M, Woithe J, Kaluza M, Pawelke J (2015) Comparison study of in vivo dose response to laser-driven versus conventional electron beam. Radiat Environ Biophys 54: 155–166

Patties I, Haagen J, Dörr W, Hildebrandt G, Glasow A (2015) Late inflammatory and thrombotic changes in irradiated hearts of C57BL/6 wild-type and atherosclerosis-prone ApoE-deficient mice. Strahlenther Onkol 191: 172–179